The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Mechanisms Of Protein Function And Pharmacology In Neuroscience And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$876,005.00
Summary
I have been a Fellow 19 years. It allows me to think strategically on a broader canvass. I am a world authority in endocytosis (how cells interact with the outside world), drug discovery, and protein function, in disciplines of neuroscience and cancer. The outcome will be the first human trials of endocytosis modulators in cancer and epilepsy. Secondly, we will use our new International ProCan Centre to produce a transformational rapid cancer diagnostic and provide new cancer treatment options.
Molecular Targeting Of Innate Immune Signalling Pathways In Cancer And Auto-Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$753,300.00
Summary
To achieve an accurate molecular understanding of innate immune system receptor signalling, both intracellularly and in whole organisms, in health and disease. This knowledge will then be used to generate better treatments for the extensive range of human diseases that are caused or exacerbated by dysfunctional innate immune signalling, including Crohn's disease, psoriasis and cancer.
This application describes a research proposal that will achieve an accurate molecular understanding of innate immune system receptor signalling in health and disease. This knowledge will then be used to generate better treatments for the extensive range of human diseases that are caused or exacerbated by dysfunctional innate immune signalling, including Crohn's disease, psoriasis and cancer.
Utilization Of Gene-engineered T Cells For Enhancing Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.
New Strategies For Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$849,540.00
Summary
The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet many patients fail to respond to this form of treatment due to low frequency of lymphocytes present at the tumor site. A new form of immunotherapy involving transfer of gene-modified lymphocytes is a potential way to overcome this problem. This project will explore new strategies to enhance the utility of this approach against blood and solid cancers.
Ovarian cancer is frequently fatal and an extremely distressing cause of death in women. Our research program draws on the Australian Ovarian Cancer Study (AOCS), involving over 2000 women with ovarian cancer to investigate the genetic causes, and molecular changes that control cancer growth and response to therapy. The program is part of Australia’s $27m commitment to the International Cancer Genomics Consortium, an ambitious, worldwide effort to map the cancer genome.
Cancer remains a major cause of morbidity and mortality in the developed & developing world. Underpinning the causes of cancer are genetic and cellular changes in key structural proteins that control cell growth and movement. My research aims to discover key links in the regulation of these proteins that lead to tumour formation, metastasis and drug resistance. My goal is to use this knowledge to develop effective and less toxic treatment strategies to target difficult-to-treat cancers.
I am a cancer researcher trained in cell biology, immunology and molecular oncology. I made major contributions to the discoveries that defects in cell death can cause cancer, autoimmune disease and impair the response of cancers to chemotherapy. My current work aims to reach a detailed understanding of the molecular mechanisms of programmed cell death and to exploit this knowledge to develop novel therapeutics for cancer and autoimmune diseases that can directly activate this process.
My research projects in the fields of cancer biology, vascular biology and immunology assess molecular mechanisms of vascular remodelling and implications for disease.
How The Bcl-2 Protein Family Controls Apoptosis And Impacts On Cancer Development And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$850,346.00
Summary
Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment ....Impaired cell death (apoptosis) is now recognized as an important step towards cancer and a major barrier to effective therapy. The discoveries on apoptosis by Professor Jerry Adams and colleagues have galvanized the search for drugs that engage the cell’s apoptotic machinery as a new way to treat cancer. His proposed studies aim to clarify how apoptosis is controlled and how the control goes awry in cancer, and to determine how such drugs can be most effectively used to improve cancer treatment.Read moreRead less